Squamous Cell Carcinoma Antigen (SCC)

Clasen, B. P. E.; Roettger, Diana; Senekowitsch, R.; Menz, E.

doi:10.1055/s-2007-998532

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die Stärke eines verlaBlichen Tuniormarkers liegt jedoch in der Rezidivdiagnostik, die sich vor allem nach Bestrahlung aufgrund der Strahlenschaden schwierig gestalten kann, aber auch in der Verlaufs-und Therapiekontrolle [2,4]. Auch [1,15]. Die Forderung für einen solchen Marker sind einerseits eine hohe Spezifität und Sensitivität, andererseits eine kostengünstige und leicht wiederholbare Routinemethode zur Bestimmung [1].…”

Section: Ounclassified

“…Auch [1,15]. Die Forderung für einen solchen Marker sind einerseits eine hohe Spezifität und Sensitivität, andererseits eine kostengünstige und leicht wiederholbare Routinemethode zur Bestimmung [1].…”

Section: Ounclassified

“…In verschiedenen Publikationen konnten erhöhte SCC-Werte (>2ng/ml) nur in 12-15% bei Walter [15], in 28% von Clasen [1] und 33% von DeryfuB [2] sowie in 38% von Fischbach [4] und Koch [7] mi Gegensatz zu den genannten konventionellen serologischen Tumormarkern, die tumorigenen Produkten entsprechen, ist der hier beschriebene igG-Subkiassen-Shift als Reaktion des Wirtsorganismus auf maligne Prozesse und sornit als indirekter Marker ohne Organspezifitat zu interpretieren. Die ursächliche Assoziation zur Malignitat ergab sich aus Versuchen mit transplantablen Tiertumoren, in denen gezeigt werden konnte, daB der Effekt die Anwesenheit vitaler, aktiv teilender Tumorzellen zur Voraussetzung hat und bereits lange vor Erreichung der exponentionellen Wachstumsphase die Signifikanzgrenze erreicht [10,16].…”

Section: Ounclassified

See 2 more Smart Citations

Quantitative Veränderungen im Immunglobulin G Subklassensystem - Ein verläßlicher Tumormarker bei Plattenepithelkarzinomen im Kopf-Hals-Bereich

Anderhuber

Steinschifter²,

Gotschuli³

et al. 1998

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

The shift in %IgG1/%IgG2 exhibited diagnostic sensitivities and specificities comparable to, or--particularly at early tumour stages--by far higher than conventional serological tumour markers. Whereas conventional serological markers directly correspond to tumourogenically derived products, the shift in %IgG1/IgG2 represents an indirect marker, consisting of a change of the host's immune system due to the presence of malignant tumours.

show abstract

Section: Ounclassified

See 1 more Smart Citation

Quantitative Veränderungen im Immunglobulin G Subklassensystem - Ein verläßlicher Tumormarker bei Plattenepithelkarzinomen im Kopf-Hals-Bereich

Anderhuber

Steinschifter²,

Gotschuli³

et al. 1998

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

show abstract

The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer

Lara

Cuyás

1995

Cancer

View full text Add to dashboard Cite

Background. The efficacy of squamous cell carcinoma antigen (SCC‐Ag) in laryngeal cancer to predict those patients who will relapse after primary treatment (surgery or radiotherapy) and its utility to detect relapses early and thereby increase salvage rates and cure were assesed. Methods. Sixty healthy donors and 168 patients with laryngeal cancer were included in this prospective trial. Squamous cell carcinoma antigen was measured at diagnosis in all patients, 24 hours and 1 week after surgery in 113 patients and every 10 Gy of administered dose and 2 weeks after treatment in 49 patients primarily referred to radiotherapy. The marker was determined every 3‐6 months during follow‐up. All patients who relapsed had SCC‐Ag studies before and after salvage treatment. Results. The selected cut‐off value was 1.5 ngr/ml (mean value in control group, 0.65 4+ 2 standard deviation [0.38]). Seventy‐eight percent of patients with cancer had elevated SCC‐Ag values at diagnosis. Squamous cell carcinoma antigen was statistically related to TNM categories (T, P < 0.04; N, P < 0.05; Stage, P < 0.01). Seventy‐five percent of those patients with previously elevated pretreatment values normalized after treatment. Incomplete surgical resection (P < 0.0001) or persistence of the disease after radiotherapy (P < 0.01) were related to high posttreatment values. Squamous cell carcinoma antigen was elevated in 88% of the patients who relapsed. In 55% of the recurrences, SCC‐Ag was elevated 3 months before pathologic confirmation of relapse. Salvage by surgery or radiotherapy was effective in 70% of the patients. Squamous cell carcinoma antigen posttreatment values were the most important factor in predicting disease free survival (DFS) (P < 0.0001) and overall survival (P < 0.03). Conclusions. Squamous cell carcinoma antigen is an excellent marker of residual disease after primary treatment that can lead to the addition of other therapeutic procedures (surgery and postoperative radiotherapy). The absence of posttreatment SCC‐Ag is the best predictor of DFS, its presence detects recurrence in early stages, permitting salvage of an increased proportion of patients primarily referred for palliative treatment.

show abstract

The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck

Anderhuber

Steinschifter²,

Schauenstein³

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

Summary A significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this phenomenon is also observed in sera of patients with squamous cell carcinoma of the head-neck region (SCC-HN), and to evaluate its diagnostic performance in the post-operative monitoring. Using quantitative affinity chromatography, serum concentrations of IgG1, IgG2 and total IgG were determined in 81 patients with different stages of primary and untreated SCC-HN, in 51 SCC-HN patients in post-therapeutical follow up, and in 33 patients with organ matched benign diseases. The data were compared with a total of 174 healthy controls. It was found that (i) 105 SCC-HN patients exhibited a mean value of 56.0 ± 0.7% IgG1, which likewise differed from healthy controls (63.2 ± 0.5) and benign diseases (61.5 ± 1.0) with P < 0.0005, (ii) sensitivities and specificities for discriminating primary malignancies from healthy controls were 70 and 74% respectively, and from benign diseases 65 and 76%, (iii) highest sensitivities and specificities were observed with posttherapeutic cases suffering from tumour recurrence (88% and 75%) or patients with distant metastases (87% and 86%), (iv) apparently tumour-free post-therapeutic patients showed a mean %IgG1 not different from the normal value. The decrease in %IgG1 accompanied by increased %IgG2 is an efficient, sensitive and early marker of SCC-HN, which appears particularly useful for the post-therapeutic monitoring.

show abstract

Squamous Cell Carcinoma Antigen (SCC)

Cited by 4 publications

References 0 publications

Quantitative Veränderungen im Immunglobulin G Subklassensystem - Ein verläßlicher Tumormarker bei Plattenepithelkarzinomen im Kopf-Hals-Bereich

Quantitative Veränderungen im Immunglobulin G Subklassensystem - Ein verläßlicher Tumormarker bei Plattenepithelkarzinomen im Kopf-Hals-Bereich

The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer

The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About